Copyright
©The Author(s) 2016.
World J Transplant. Dec 24, 2016; 6(4): 697-702
Published online Dec 24, 2016. doi: 10.5500/wjt.v6.i4.697
Published online Dec 24, 2016. doi: 10.5500/wjt.v6.i4.697
Table 5 Graft loss n (%)
| Parameter | Tacrolimus n = 106 | Cyclosporine n = 123 | P-value |
| Death with functioning graft | 61 (58) | 66 (54) | 0.55 |
| Cause of death | 0.85 | ||
| Cardiovascular disease | 19 (18) | 19 (15) | |
| Infections | 10 (9) | 9 (7) | |
| Malignancy | 10 (9) | 9 (7) | |
| Others | 33 (31) | 41 (33) | |
| Causes of graft loss | 0.44 | ||
| Chronic allograft nephropathy | 18 (17) | 29 (24) | |
| Acute rejection | 14 (13) | 11 (9) | |
| Acute on chronic rejection | 8 (8) | 13 (11) | |
| Recurrent disease | 1 (1) | 1 (1) | |
| Death | 63 (59) | 68 (55) | |
| Component of non- adherence | 15 (14) | 20 (16) | 0.65 |
| Component of underimmunosuppression | 21 (20) | 25 (20) | 0.92 |
- Citation: Kamel M, Kadian M, Srinivas T, Taber D, Posadas Salas MA. Tacrolimus confers lower acute rejection rates and better renal allograft survival compared to cyclosporine. World J Transplant 2016; 6(4): 697-702
- URL: https://www.wjgnet.com/2220-3230/full/v6/i4/697.htm
- DOI: https://dx.doi.org/10.5500/wjt.v6.i4.697